On Tuesday, Arbutus Biopharma Corp (NASDAQ: ABUS) was -0.29% drop from the session before settling in for the closing price of $3.49. A 52-week range for ABUS has been $2.30 – $4.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 41.91% over the past five years. When this article was written, the company’s average yearly earnings per share was at 43.68%. With a float of $148.63 million, this company’s outstanding shares have now reached $189.96 million.
Let’s look at the performance matrix of the company that is accounted for 44 employees. In terms of profitability, gross margin is 88.48%, operating margin of -1230.4%, and the pretax margin is -1133.04%.
Arbutus Biopharma Corp (ABUS) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arbutus Biopharma Corp stocks. The insider ownership of Arbutus Biopharma Corp is 22.38%, while institutional ownership is 54.40%. The most recent insider transaction that took place on Mar 31 ’25, was worth 875,000. Before that another transaction happened on Mar 24 ’25, when Company’s Officer proposed sale 250,000 for $3.28, making the entire transaction worth $820,000.
Arbutus Biopharma Corp (ABUS) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 43.68% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 49.14% during the next five years compared to 33.46% growth over the previous five years of trading.
Arbutus Biopharma Corp (NASDAQ: ABUS) Trading Performance Indicators
You can see what Arbutus Biopharma Corp (ABUS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.15. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 108.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.38, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.10 in one year’s time.
Technical Analysis of Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (NASDAQ: ABUS) saw its 5-day average volume 1.26 million, a positive change from its year-to-date volume of 0.89 million. As of the previous 9 days, the stock’s Stochastic %D was 81.59%. Additionally, its Average True Range was 0.16.
During the past 100 days, Arbutus Biopharma Corp’s (ABUS) raw stochastic average was set at 48.94%, which indicates a significant decrease from 72.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 40.82% in the past 14 days, which was lower than the 42.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.35, while its 200-day Moving Average is $3.59. Nevertheless, the first resistance level for the watch stands at $3.58 in the near term. At $3.69, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.77. If the price goes on to break the first support level at $3.39, it is likely to go to the next support level at $3.31. Assuming the price breaks the second support level, the third support level stands at $3.20.
Arbutus Biopharma Corp (NASDAQ: ABUS) Key Stats
There are 191,480K outstanding shares of the company, which has a market capitalization of 666.35 million. As of now, sales total 6,170 K while income totals -69,920 K. Its latest quarter income was 1,570 K while its last quarter net income were -12,530 K.
